Compare Thomson Reuters Corp (TRI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Thomson Reuters Corp trades at $103.08 (market cap $43.89B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays a 2.58% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Thomson Reuters Corp for 63 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TRI | VRTX | |
|---|---|---|
Market Cap | $43.89B | $127.55B |
Volume | 1,648,199 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $163.45 | $557.96 |
52-Week Low | $76.55 | $407.37 |
Typical Hold Time | 63 Days | 120 Days |
Enterprise Value | $46.51B | $121.68B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $101.71, up 2.45% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with a 21.22% net income margin and 10% organic growth in core businesses. Recent strategic moves include divesting its print unit to focus on technology and launching a proprietary AI model, positioning for future growth.
The outlook is positive with a consensus price target of $133.25, implying significant upside. Key risks include execution of the AI strategy and cybersecurity concerns. Institutional buying and insider purchases support confidence, but investors should monitor earnings performance and competitive pressures in the legal tech space.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
